Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biogen Idec
(NQ:
BIIB
)
224.00
-1.58 (-0.70%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Biogen Idec
< Previous
1
2
...
18
19
20
21
22
23
24
25
26
...
38
39
Next >
Why Scholar Rock Shares Are Trading Higher Today
June 17, 2022
Via
Benzinga
Roche's Alzheimer's Failures Keep Piling Up; Can The Stock Recover?
June 16, 2022
Roche hoped to prevent Alzheimer's disease in patients with a genetic defect.
Via
Investor's Business Daily
The Daily Biotech Pulse: Roche's Alzheimer's Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK
June 16, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Karyopharm Therapeutics' Shares Slide After Biogen Terminates 2018 Asset Purchase Agreement
June 15, 2022
Via
Benzinga
Analyzing Biogen's Short Interest
June 10, 2022
Biogen's (NASDAQ:BIIB) short percent of float has risen 8.63% since its last report. The company recently reported that it has 2.20 million shares sold short, which is 1.51% of...
Via
Benzinga
Read Why Biogen Sares Are Trading Higher After Q1 Earnings
May 03, 2022
Via
Benzinga
Biogen Pops On New Plans For Its Embattled Alzheimer's Drug, Aduhelm
May 03, 2022
The decision comes after Medicare officials severely limited coverage of Aduhelm.
Via
Investor's Business Daily
Recap: Biogen Q1 Earnings
May 03, 2022
Biogen (NASDAQ:BIIB) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
$100 Invested In Biogen 20 Years Ago Would Be Worth This Much Today
June 09, 2022
Biogen (NASDAQ:BIIB) has outperformed the market over the past 20 years by 2.47% on an annualized basis producing an average annual return of 9.5%. Currently, Biogen has a market capitalization of...
Via
Benzinga
7 No-Brainer Biotech Stocks to Add to Your Buy List
June 09, 2022
With the broader markets grumbling, investors should consider biotech stocks to buy for their permanently relevant profile.
Via
InvestorPlace
Quant Ratings Updated on 66 Stocks
June 06, 2022
Out of the 66 stocks that were upgraded/downgraded this weekend, 12 were downgraded to a D-rating. And I'm giving you the first 10.
Via
InvestorPlace
Sage Therapeutics And Biogen Tackle Depression — And Their Stocks Do The Same
June 01, 2022
Sage and Biogen say their MDD drug met every goal in a study of postpartum women.
Via
Investor's Business Daily
$1000 Invested In Biogen 15 Years Ago Would Be Worth This Much
May 31, 2022
Biogen (NASDAQ:BIIB) has outperformed the market over the past 15 years by 3.1% on an annualized basis producing an average annual return of 10.04%. Currently, Biogen has a market capitalization of...
Via
Benzinga
Biogen Fails To Convince Benefits Of Alzheimer's Drug To European Regulator
April 22, 2022
Via
Benzinga
Why Is Catalyst Biosciences (CBIO) Stock Soaring 170% Today?
May 23, 2022
Catalyst Biosciences (CBIO) stock is rocketing higher on Monday after announcing the sale of its protease medicines portfolio.
Via
InvestorPlace
Catalyst Biosciences Stock More Than Doubles After Assets Sale To Vertex
May 23, 2022
Via
Benzinga
Morning Brief: Top Financial Stories Dominating on Monday, May 23
May 23, 2022
CNBC US Announces Asia Economic Deal To Strengthen Foothold, Check China
Via
Benzinga
Researchers Investigate New Treatment Pathways For Alzheimer's After Commercial Failure Of Biogen's Aduhelm
May 23, 2022
The commercial failure of Biogen Inc's (NASDAQ: BIIB) drug Aduhelm has put a new focus on the research into the causes of Alzheimer's disease.
Via
Benzinga
Biogen Pops After Eisai Asks FDA To Approve A New Alzheimer's Treatment
May 10, 2022
Eisai finished submitting its application for lecanemab, another anti-amyloid drug.
Via
Investor's Business Daily
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
May 10, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Eisai - Biogen Seek Accelerated Approval For Their Second Alzheimer's Drug
May 10, 2022
Via
Benzinga
Looking Into Biogen's Return On Capital Employed
May 04, 2022
According to Benzinga Pro, during Q1, Biogen (NASDAQ:BIIB) earned $218.50 million, a 1165.85% increase from the preceding quarter. Biogen's sales decreased to $2.53 billion, a 7.39% change since Q4.
Via
Benzinga
Stock Market Jumps, Then Dives After Fed Rate Hikes As Treasury Yields Soar: Weekly Review
May 06, 2022
Lithium plays jump on earnings, but Nasdaq at lowest level since 2020.
Via
Investor's Business Daily
10 Biggest Price Target Changes For Wednesday
May 04, 2022
RBC Capital boosted Atkore Inc. (NYSE: ATKR) price target from $123 to $170. Atkore shares rose 0.2% to $109.00 in pre-market trading.
Via
Benzinga
BIIB Stock Treks Higher Amid News That Biogen CEO Michel Vounatsos Is Stepping Down
May 03, 2022
Drug-making giant Biogen is in the green today after announcing CEO Michel Vounatsos is stepping down from the role.
Via
InvestorPlace
Biogen Inc. Q1 Earnings Miss Estimates
May 03, 2022
Biogen Inc. came out with quarterly earnings of $3.62 per share.
Via
Talk Markets
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
May 03, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Sage Therapeutics, Biogen Start Rolling Submission For Zuranolone In Major Depressive Disorder
May 02, 2022
Via
Benzinga
Earnings Preview For Biogen
May 02, 2022
Biogen (NASDAQ:BIIB) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement. Analysts estimate that Biogen will report an...
Via
Benzinga
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
May 02, 2022
Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks...
Via
Benzinga
< Previous
1
2
...
18
19
20
21
22
23
24
25
26
...
38
39
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.